These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16633997)

  • 21. [Activation of the renin-angiotensin-aldosterone system in heart failure].
    Volpe M; Tocci G; Pagannone E
    Ital Heart J; 2005 May; 6 Suppl 1():16S-23S. PubMed ID: 15945296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aldosterone receptor antagonism and heart failure: insights from an outpatient clinic.
    Mariotti R; Borelli G; Coceani M; Zingaro S; Barison A; Morelli I; Rondinini L
    J Clin Pharm Ther; 2008 Aug; 33(4):349-56. PubMed ID: 18613852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myocardial collagen matrix remodeling and congestive heart failure.
    Brilla CG; Rupp H
    Cardiologia; 1994 Dec; 39(12 Suppl 1):389-93. PubMed ID: 7634301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure).
    Boccanelli A; Cacciatore G; Mureddu GF; de Simone G; Clemenza F; De Maria R; Di Lenarda A; Gavazzi A; Latini R; Masson S; Porcu M; Vanasia M; Gonzini L; Maggioni AP
    J Cardiovasc Med (Hagerstown); 2007 Sep; 8(9):683-91. PubMed ID: 17700397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
    Chrysostomou A; Pedagogos E; MacGregor L; Becker GJ
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):256-62. PubMed ID: 17699214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy.
    Tan LB; Schlosshan D; Barker D
    Int J Cardiol; 2004 Sep; 96(3):321-33. PubMed ID: 15310530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia.
    Palazzuoli A; Silverberg DS; Calabrò A; Spinelli T; Quatrini I; Campagna MS; Franci B; Nuti R
    J Cardiovasc Pharmacol; 2009 Jun; 53(6):462-7. PubMed ID: 19455052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.
    Krum H; Ashton E; Reid C; Kalff V; Rogers J; Amarena J; Singh B; Tonkin A
    J Card Fail; 2007 Feb; 13(1):1-7. PubMed ID: 17338996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload.
    Ryan TD; Rothstein EC; Aban I; Tallaj JA; Husain A; Lucchesi PA; Dell'Italia LJ
    J Am Coll Cardiol; 2007 Feb; 49(7):811-21. PubMed ID: 17306712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S
    Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts.
    Takeda M; Tatsumi T; Matsunaga S; Hayashi H; Kimata M; Honsho S; Nishikawa S; Mano A; Shiraishi J; Yamada H; Takahashi T; Matoba S; Kobara M; Matsubara H
    Hypertens Res; 2007 May; 30(5):427-37. PubMed ID: 17587755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M; Solomon SD
    Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The therapeutic role of RAS blockade in chronic heart failure.
    Werner CM; Böhm M
    Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):167-77. PubMed ID: 19124420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure.
    Bartha E; Kiss GN; Kalman E; Kulcsár G; Kálai T; Hideg K; Habon T; Sumegi B; Toth K; Halmosi R
    J Cardiovasc Pharmacol; 2008 Sep; 52(3):253-61. PubMed ID: 18806606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factor-induced cardiovascular remodeling and the effects of angiotensin-converting enzyme inhibitors.
    Galderisi M; de Divitiis O
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):523-31. PubMed ID: 18520954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antialdosteronic therapy in mild chronic heart failure: from AREA IN-CHF to EMPHASIS-HF].
    Boccanelli A
    Recenti Prog Med; 2010 Oct; 101(10):402-5. PubMed ID: 21137577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies to attenuate pathological remodeling in heart failure.
    Eapen Z; Rogers JG
    Curr Opin Cardiol; 2009 May; 24(3):223-9. PubMed ID: 19318933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction.
    Huang BS; White RA; Ahmad M; Tan J; Jeng AY; Leenen FH
    Cardiovasc Res; 2009 Feb; 81(3):574-81. PubMed ID: 18689429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.
    Palazzuoli A; Silverberg DS; Iovine F; Calabrò A; Campagna MS; Gallotta M; Nuti R
    Am Heart J; 2007 Oct; 154(4):645.e9-15. PubMed ID: 17892986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.